



C: Institut Pasteur in Italy – Cenci Bolognetti Foundation




Science **336** (6088), 1531-1533. DOI: 10.1126/science.1221466

POLICY FORUM

Influenza: Options to Improve Pandemic Preparation

Rino Rappuoli¹* and Philip R. Dormitzer²








Transforming Vaccine Development

Vaccine Vision in 2011



Rino Rappuoli 1 & Alan Aderem 2

26 MAY 2011 | VOL 473 | NATURE | 467






Transforming Vaccine Development

to Make Vaccines Available Faster



Palio meeting, Rockville, July 1st 2019 Seminar at Stanford University January 17th 2020





Vaccines in 10 Months



- Technology
- Unprecedented investement by the public sector



Technologies

4 technologies allowed fast development of Covid-19 vaccines







Sunday March 31st 2013 Easter day

- Chinese CDC postes the sequence of an H7N9 avian influenza virus
- The virus had already killed 3 people, high risk of influenza pandemic
- Race for vaccine developement starts
- Virus had to be sent from China to CDC in Atlanta



Synthetic Generation of Influenza Vaccine Viruses for Rapid Response to Pandemics

Philip R. Dormitzer et al.

Sci Transl Med 5, 185ra68 (2013); DOI: 10.1126/scitranslmed.3006368

Emerging Microbes and Infections (2013) 2, e52; doi:10.1038/emi.2013.54 © 2013 SSCC. All rights reserved 2222-1751/13


www.nature.com/emi





2013: Internet & Synthetic Biology-based Vaccines in One Week

In 2013 an RNA vaccine and a virus seed in one week using information teleported by internet





Synthetic Generation of Influenza Vaccine Viruses for Rapid Response to Pandemics

Philip R. Dormitzer *et al. Sci Transl Med* **5**, 185ra68 (2013); DOI: 10.1126/scitranslmed.3006368

eline from electronic gene sequence posting to production of RNA prior to formulation with the LNP delivery system. GISAID, Global Initiative for Sharin

sequence verified and

linearized for transcription

Emerging Microbes and Infections (2013) 2, e52; doi:10.1038/emi.2013.54 © 2013 SSCC. All rights reserved 2222-1751/13

at NV&D; Cloning into SAM

......




agarose gel; expression of H


by SAM vector confirmed by




Shipping Information Instead of Viruses




from **Analog** to **Digital** vaccines







Accessible Vaccines Globally and even in Mars








January 10th 2020 SARS-CoV-2 Sequence Posted in Internet

350 labs worldwide used the sequence to make synthetic genes



PNAS 2021 Vol. 118 No. 3 e2020368118

https://doi.org/10.1073/pnas.2020368118 | 1 Vaccinology in the post—COVID-19 era

Rino Rappuoli^{a,1}, Ennio De Gregorio^a, Giuseppe Del Giudice^a, Sanjay Phogat^a, Simone Pecetta^a,





Three Main Vaccine Types for Covid-19

Immunogenicity





Novavax, Sanofi/GSK, Clover/Dynavax, Medicago/GSK, SK/GSK




Moderna, BionTech/Pfizer, Curevac

Viral vectors



Oxford/Astra Zeneca, J&J, Reithera Russian Vaccine, Chinese vaccines




Neutralizing antibodies from Phase I clinical studies





Three Main Vaccine Types for Covid-19 *Efficacy*







Vaccines in 10 Months

Technology




Unprecedented investement by the public sector





Classical Vaccine Development







Unprecedented Acceleration of Vaccine Develoment


Investment > 15 billion investment from the public sector (>10 billion USA alone) in vaccine

Development and Manufacturing allowed at risk development (parallel investment in discovery, early and late development)



Pre-Covid Vaccines

10-20 years




Covid Vaccines

10 months





The trillion dollar vaccine gap



The trillion dollar vaccine gap

Simone Pecetta¹, Daniel Tortorice², Francesco Berlanda Scorza³, Mariagrazia Pizza³ Gordon Dougan⁴, Richard Hatchett⁵, Steve Black⁶, David E. Bloom⁷, Rino Rappuoli¹*

Pecetta et al., Sci. Transl. Med. 14, eabn4342 (2022) 30 March 2022






Cite as: B. A. Cohn *et al.*, *Science* 10.1126/science.abm0620 (2021).


SARS-CoV-2 vaccine protection and deaths among US veterans during 2021

Barbara A. Cohn¹†, Piera M. Cirillo^{1,2}†, Caitlin C. Murphy³†, Nickilou Y. Krigbaum^{1,2}, Arthur W. Wallace^{2,4*}






From basic Immunology textbooks







From basic Immunology textbooks








4th Dose COVID mRNA Vaccines' Immunogenicity & Efficacy Against Omicron VOC

Gili Regev-Yochay^{1,2}, Tal Gonen^{1,2}, Mayan Gilboa^{1,2}, Michal Mandelboim^{2,3}, Victoria Indenbaum³, Sharon Amit⁴, Lilac Meltzer^{1,2}, Keren Asraf⁵, Carmit Cohen¹, Ronen Fluss⁶, Asaf Biber^{1,2}, Ital Nemet³, Limor Kliker^{2,3}, Gili Joseph¹, Ram Doolman⁵, Ella Mendelson^{2,3}, Laurence S. Freedman⁶, Dror Harats⁷, Yitshak Kreiss*⁷ and Yaniv Lustig*^{2,3}

medRxiv preprint doi: https://doi.org/10.1101/2022.02.15.22270948; t









Why Vaccines Protect Poorly from Infection but Protect Well from Severe Disease and Long Covid

Simone Pecetta and Rappuoli in preparation





Omicron Infection or Vaccination is Expected to Boost Immunity to Subdominant Crossreactive Epitopes








Vaccination and Infection Induce Different Classes of Omicron Neutralizing Antibodies

Emanuele Andreano submitted










SARS-CoV-2 Spike protein suppresses CTL-mediated killing by inhibiting immune synapse assembly

SARS-CoV-2 Spike Suppresses CTL-Mediated Killing

Anna Onnis¹, Emanuele Andreano², Chiara Cassioli¹, Francesca Finetti¹, Elisa Pantano², Valentina Abbiento², Giuseppe Marotta³, Rino Rappuoli^{2,4}, Cosima T Baldari¹












Monoclonal and Vaccines Provide the Fastest Response for a Pandemic





Governments Invested but not Enough

- 12.5 billion warp speed paid itself by anticipating vaccination by just 12 hours (Micheal Kremer)
- More investments would have had high returns
- Additional manufacturing capacity in early 2021 was needed
- Early manufacturing capacity necessary to improve equity
- Developing one vaccine requires more than 34 billion



A Center for Pandemic Preparedness in Siena, Italy

Spediz. abb. post. - art. 1, comma 1 Legge 27-02-2004, n. 46 - Filiale di Roma



Anno 163° - Numero 199

LITTA OLITICIALLI

DELLA REPUBBLICA ITALIANA

PARTE PRIMA

Roma - Venerdì, 26 agosto 2022

SI PUBBLICA TUTTI I Giorni non festivi

DIREZIONE E REDAZIONE PRESSO IL MINISTERO DELLA GIUSTIZIA - UFFICIO PUBBLICAZIONE LEGGI E DECRETI - VIA ARENULA, 70 - 00186 ROMA Amministrazione presso l'istituto poligrafico e zecca dello stato - via salaria, 691 - 00138 Roma - centralino 06-85081 - libreria dello stato Piazza G. Verdi. 1 - 00198 Roma

DECRETO DEL PRESIDENTE DEL CONSIGLIO DEI MINISTRI 11 luglio 2022.

Approvazione dello statuto della Fondazione «Biotecnopolo di Siena».

> IL PRESIDENTE DEL CONSIGLIO DEI MINISTRI



A center for Pandemic Preparedness in Siena, Italy

- A National Center, well funded by the Italian Government up to the end of 2026
- The ambition to be a resource for Europe and for the world
- To be part of a global network of Institutes preparing the world for new pandemics (collaborate with CEPI, CARBX, BMGF, NIH, Wellcome Trust, etc..) including antimicrobial resistance
- Discovery, GMP up to phase 2B, for emergency approval
- To be started in 2022





Thank you!

